Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06569082
NA

CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure

Sponsor: NYU Langone Health

View on ClinicalTrials.gov

Summary

The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.

Official title: CD34+ Selected Donor Cell Boost for Management of Poor Graft Function or Primary or Secondary Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

21

Start Date

2024-10-31

Completion Date

2035-08

Last Updated

2025-09-29

Healthy Volunteers

No

Interventions

DEVICE

CD34+ Selected Donor Cell Boost

The CliniMACS CD34 Reagent System is used to separate CD34 cells from the remaining stem cell product, using a peripheral blood stem cell sample provided by the original donor. These CD34 cells are then infused into the recipient following selection with the intent to restore function of the blood forming cells.

PROCEDURE

Blood Stem Cell Infusion

The selected CD34 cells separated by the CliniMACS CD34 Reagent System are infused into the recipient.

Locations (1)

NYU Langone Health

New York, New York, United States